THE CORPORATE LIBRARY

Related Party Transactions and Outside Related Director Information

Minerals Technologies Inc. (MTX)

4/4/2006 Proxy Information

Mr. Golub, a director of Minerals Technologies Inc., is Managing Director and Vice Chairman of Lazard LLC (“Lazard”). Minerals Technologies Inc. has engaged Lazard to provide investment banking services from time to time with respect to a variety of financial matters. No such services were provided during 2005. Lazard acts as our broker in connection with our ongoing program of repurchases of a portion of our outstanding common stock. To obtain this business, Lazard in an arm’s-length transaction, agreed to meet a competitive bid structured as a fixed commission on each share repurchased. Payments by the Company to Lazard in connection with such brokerage services were approximately $39,550 during 2005.

Mr. Muscari, a director of Minerals Technologies Inc., is Executive Vice President and Chief Financial Officer of Alcoa Inc. During 2005, Alcoa Inc. made a series of purchases of refractory products from Minerals Technologies Inc. totaling $105,347. In addition, during 2005 Alcoa Inc. made a series of sales of metallurgical raw materials to Minerals Technologies Inc. totaling $796,000. These transactions were entered into by Minerals Technologies Inc. pursuant to arm’s-length negotiations in the ordinary course of business and on terms that we believe to be fair.

Dr. VallŹs, a director of Minerals Technologies Inc., served as a member of the Board of Directors of Pfizer Inc. until June 2005. During 2005, Pfizer Inc. made a series of purchases of precipitated calcium carbonate from Minerals Technologies Inc. totaling $1,684,000. These transactions were entered into by Minerals Technologies Inc. pursuant to arm’s-length negotiations in the ordinary course of business and on terms that we believe to be fair.

4/4/2005 Proxy Information

Dr. VallŹs, who is a director and former Chairman and Chief Executive Officer of Minerals Technologies Inc., is a member of the Board of Directors of Pfizer Inc. During 2004, Pfizer Inc. made a series of purchases of precipitated calcium carbonate from Minerals Technologies Inc. totaling approximately $1.5 million. These transactions were entered into by Minerals Technologies Inc. pursuant to arm's-length negotiations in the ordinary course of business and on terms that we believe to be fair.

Mr. Golub, a director of Minerals Technologies Inc., is Managing Director and Vice Chairman of Lazard LLC (“Lazard”). Minerals Technologies Inc. has engaged Lazard to provide investment banking services from time to time with respect to a variety of financial matters. During 2004, Minerals Technologies Inc. paid Lazard approximately $55,700 for investment banking services in connection with a terminated acquisition. In addition, Lazard acts as our broker in connection with our ongoing program of repurchases of a portion of our outstanding common stock. To obtain this business, Lazard in an arm's-length transaction, agreed to meet a competitive bid structured as a fixed commission on each share repurchased. Payments by the Company to Lazard in connection with such brokerage services were approximately $14,655 during 2004.

4/2/2004 Proxy Information

Mr. Steere, who was a director of Minerals Technologies until December 31, 2003, is a director and former Chairman and Chief Executive Officer of Pfizer Inc. Dr. Valles, who is a director and former Chairman and Chief Executive Officer of Minerals Technologies, is a member of the Board of Directors of Pfizer Inc. During 2003, Pfizer Inc. made a series of purchases of precipitated calcium carbonate from Minerals Technologies totaling approximately $1.6 million. These transactions were entered into by Minerals Technologies pursuant to arm's-length negotiations in the ordinary course of business and on terms that we believe to be fair.

Mr. Golub, a director of Minerals Technologies, is Managing Director of Lazard Freres & Co. LLC. Minerals Technologies has engaged Lazard Freres to provide investment banking services from time to time with respect to a variety of financial matters. No such services were provided during 2003. In addition, Lazard Freres acts as our broker in connection with our ongoing program of repurchases of a portion of our outstanding common stock. To obtain this business, Lazard Freres, in an arm's-length transaction, agreed to meet a competitive bid structured as a fixed commission on each share repurchased. Payments by the Company to Lazard Freres in connection with such brokerage services were less than $10,000 during 2003.

3/31/2003 Proxy Information

Mr. Steere, who is a director of Minerals Technologies, is a director and former Chairman and Chief Executive Officer of Pfizer Inc. Dr. Valles, who is a director and former Chairman and Chief Executive Officer of Minerals Technologies, is a member of the Board of Directors of Pfizer Inc. During 2002, Pfizer Inc. made a series of purchases of precipitated calcium carbonate from Minerals Technologies totaling approximately $1.7 million. These transactions were entered into by Minerals Technologies pursuant to arm's-length negotiations in the ordinary course of business and on terms that we believe to be fair.

Mr. Golub, a director of Minerals Technologies, is Managing Director of Lazard Freres & Co. LLC. Minerals Technologies has engaged Lazard Freres to provide investment banking services from time to time with respect to a variety of financial matters. In addition, Lazard Freres acts as our broker in connection with our ongoing program of repurchases of a portion of our outstanding common stock. To obtain this business, Lazard Freres, in an arm's-length transaction, agreed to meet a competitive bid structured as a fixed commission on each share repurchased.